Companies Cryptocurrencies
Advaxis Inc
Advaxis Inc
Exchange: Nasdaq Global Select
IPO Date: 28/07/2005
CEO: Mr. Kenneth Berlin
Biotechnology Healthcare 🔗
  • ADXS
  • 0.516
  • 75149208
    market cap
  • 0.01129997
If you bought

shares of Advaxis Inc (ADXS) on
You would have made
Old Price $12 Current Price $12

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Princeton, New Jersey and currently employs 35 full-time employees. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Address: 305 College Rd E Princeton NEW JERSEY 08540

Stay updated.